An update on gene therapy in Parkinson's disease (Q37863587)

24 August 2017

1 reference

title

An update on gene therapy in Parkinson's disease (English)

1 reference

24 August 2017

0 references

1 reference

Jennifer Witt

1

1 reference

24 August 2017

William J Marks

series ordinal

2

1 reference

24 August 2017

publication date

1 August 2011

1 reference

Current Neurology and Neuroscience Reports

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

362-370

1 reference

Success and problems of long-term levodopa therapy in Parkinson's disease

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Parkinson's disease. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Parkinson's disease. Second of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

The scientific and clinical basis for the treatment of Parkinson disease (2009).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Posteroventral medial pallidotomy in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Genetic fate of recombinant adeno-associated virus vector genomes in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Stable gene transfer to the nervous system using a non-primate lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Dopaminergic neurons protected from degeneration by GDNF gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

The subthalamic nucleus in the context of movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Subthalamic GAD gene therapy in a Parkinson's disease rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Neurturin, a relative of glial-cell-line-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Localized striatal delivery of GDNF as a treatment for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Treatment of Parkinson's disease with trophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Occurrence of leukaemia following gene therapy of X-linked SCID.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Volunteering for early phase gene transfer research in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-011-0197-8

Dopamine (3-hydroxytyramine) and brain function

21 January 2018

1 reference

12 December 2020

Test-retest reliability of UPDRS-III, dyskinesia scales, and timed motor tests in patients with advanced Parkinson's disease: an argument against multiple baseline assessments

1 reference

12 December 2020

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

1 reference

12 December 2020

Preventing levodopa-induced dyskinesias

1 reference

12 December 2020

Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration.

1 reference

12 December 2020

Gene therapy for dopamine replacement in Parkinson's disease

1 reference

12 December 2020

Intricate regulation of tyrosine hydroxylase activity and gene expression

1 reference

12 December 2020

Behavioral effects and gene delivery in a rat model of Parkinson's disease

1 reference

12 December 2020

Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

1 reference

12 December 2020

Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat

1 reference

12 December 2020

Etiology of Parkinson's disease

1 reference

12 December 2020

Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.

1 reference

12 December 2020

GTP cyclohydrolase I gene, dystonia, juvenile parkinsonism, and Parkinson's disease

1 reference

12 December 2020

Glial cell line-derived neurotrophic factor-secreting genetically modified human bone marrow-derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease

1 reference

12 December 2020

Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons

1 reference

12 December 2020

The neurochemistry of Parkinson's disease: effect of L-dopa therapy

1 reference

12 December 2020

Complications and limitations of drug therapy for Parkinson's disease.

1 reference

12 December 2020

Efficient transduction of human neurons with an adeno-associated virus vector

1 reference

12 December 2020

Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors

1 reference

12 December 2020

10.1007/S11910-011-0197-8

Identifiers

DOI

1 reference

24 August 2017

1 reference